IL1A and congenital rubella syndrome: IL-1 is thought to exacerbate CRS, and phase 3 randomized control trial (RCT) of sepsis patients showed that IL-1 receptor antagonist anakinra (already approved for the treatment of rheumatoid arthritis) demonstrated survival benefits for patients with hyperinflammation [46, 108].